Tema Etfs LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Tema Etfs LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel.com reports. The fund purchased 30,846 shares of the biopharmaceutical company’s stock, valued at approximately $2,849,000. Gilead Sciences comprises approximately 1.2% of Tema Etfs LLC’s holdings, making the stock its 28th biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Toronto Dominion Bank raised its position in shares of Gilead Sciences by 11.0% in the fourth quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company’s stock valued at $65,631,000 after purchasing an additional 70,551 shares during the period. Royal Bank of Canada raised its position in shares of Gilead Sciences by 30.1% in the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company’s stock valued at $801,655,000 after purchasing an additional 2,005,863 shares during the period. Raiffeisen Bank International AG bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $21,594,000. Redwood Financial Network Corp raised its position in shares of Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $11,164,000. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 25,429 shares of company stock worth $2,894,445 over the last quarter. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several research reports. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $102.50 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market cap of $127.50 billion, a price-to-earnings ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26. The company’s fifty day moving average is $105.75 and its 200 day moving average is $99.76.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. Gilead Sciences’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.08%. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.